Ginkgo Bioworks Holdings, Inc. income statement

In fiscal 2025, Ginkgo Bioworks Holdings, Inc. reported revenue of $170m, down 25.1% on the year before, operating income of −$315m (a -185.3% margin) and net income of −$313m, or −$5.64 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ginkgo Bioworks Holdings, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	54	77	314	478	251	227	170	112
Research and development	96	160	1,150	1,053	581	424	244	216
General and administrative	29	38	863	1,430	385	246	183	160
Operating income	−72	−137	−1,828	−2,209	−864	−560	−315	−291
Interest expense	2	2	2	0	0	0	0	—
Net interest income	−48	12	−10	—	—	—	—	—
Income before tax	−120	−125	−1,838	−2,121	−893	−548	−314	−295
Income tax	0	2	−1	−15	−0	−0	−1	−1
Net income	−119	−127	−1,830	−2,105	−893	−547	−313	−291
Diluted EPS	−$4.00	−$4.00	−$55.60	−$50.20	−$18.37	−$10.54	−$5.64	−$4.96
Diluted shares (average)	29m	32m	34m	42m	49m	52m	55m	59m
EBITDA	−61	−123	−1,799	−2,166	−794	−497	−256	−237

US$ millions unless shown otherwise. Fiscal quarters.

Ginkgo Bioworks Holdings, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	89	44	38	39	39	33	19	20
Cost of revenue	—	—	4	5	—	—	3	2
Gross profit	—	—	34	34	—	—	16	18
Research and development	77	76	71	53	69	50	50	46
General and administrative	52	57	40	35	45	46	38	31
Operating income	−55	−104	−81	−58	−90	−71	−71	−59
Interest expense	−9	31	—	—	—	—	—	—
Net interest income	9	—	6	6	6	—	4	3
Income before tax	−57	−108	−83	−53	−81	−81	−76	−57
Income tax	−0	−0	0	−0	0	−1	−0	0
Net income	−56	−108	−91	−60	−81	−81	−83	−47
Diluted EPS	−$1.08	−$1.96	−$1.68	−$1.10	−$1.45	−$1.42	—	—
EBITDA	−38	−88	−66	−43	−75	−57	−59	−46

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DNA vs SPRY DNA vs RCUS DNA vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ginkgo Bioworks Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ginkgo Bioworks Holdings, Inc.